12 Health Care Stocks Moving In Wednesday's Intraday Session

Benzinga · 20h ago
Gainers
- Ensysce Biosciences (NASDAQ:ENSC) shares moved upwards by 81.3% to $3.39 during Wednesday's regular session. The company's market cap stands at $4.7 million.
- Sonoma Pharmaceuticals (NASDAQ:SNOA) stock rose 60.5% to $3.74. The company's market cap stands at $6.0 million.
- Silexion Therapeutics (NASDAQ:SLXN) stock moved upwards by 50.78% to $1.06. The market value of their outstanding shares is at $9.2 million.
- Plus Therapeutics (NASDAQ:PSTV) shares moved upwards by 39.82% to $1.1. The company's market cap stands at $6.4 million.
- Pluri (NASDAQ:PLUR) shares increased by 32.91% to $6.38. The market value of their outstanding shares is at $44.6 million.
- Relmada Therapeutics (NASDAQ:RLMD) shares moved upwards by 30.31% to $0.49. The company's market cap stands at $16.3 million.
Losers
- Ocean Biomedical (NASDAQ:OCEA) stock fell 34.3% to $0.03 during Wednesday's regular session. The market value of their outstanding shares is at $4.2 million.
- Intensity Therapeutics (NASDAQ:INTS) stock decreased by 27.29% to $1.39. The company's market cap stands at $21.0 million.
- China SXT Pharmaceuticals (NASDAQ:SXTC) shares decreased by 17.79% to $1.71. The company's market cap stands at $23.5 million.
- Phio Pharma (NASDAQ:PHIO) shares decreased by 17.53% to $2.07. The market value of their outstanding shares is at $9.8 million.
- Artelo Biosciences (NASDAQ:ARTL) shares declined by 11.54% to $1.03. The market value of their outstanding shares is at $3.3 million.
- Revelation Biosciences (NASDAQ:REVB) shares fell 10.77% to $2.86. The company's market cap stands at $2.5 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.